With the participation of TSLP as an enhancer, TSLP-activated DCs can induce much robust CD8+ T cell expansion, thus providing more efficient anti-tumor immunotherapies than historically used adjuvant Bacillus Calmette–Guérin (88). This evidence concerns the gene CD8A and neoplasm.